Medical technology company Pexa reports increased revenue and improved profit for the first quarter of 2026 compared with the corresponding period the previous year. Net sales amounted to SEK 1.1 million (0). Profit after financial items improved to SEK -1.0 million (-2.2). Earnings per share amounted to SEK 0.01 (-0.04). Cash and cash equivalents at the end of the period amounted to SEK 3.8 million (3.9) and the equity ratio was 76.5 percent (77.6). Operating profit improved to SEK -1.0 million (-2.3). According to the company, the improvement is explained by increased net sales and capitalization of development work linked to the company's platform. The board assesses that the company's available funds are not sufficient to finance the next twelve months of operations and is therefore evaluating various financing alternatives. "Overall, Pexa has taken several steps in the right direction in the beginning of 2026. Our focus remains on building long-term value through customer relationships, references, data, patents and user outcomes", writes CEO Tomas Gustafsson. Pexa, SEK millionQ1 2026Q1 2025Revenue1.10Operating profit-1.0-2.3Profit before tax-1.0-2.2Net profit-1.0-2.2Earnings per share, kronor0.01-0.04